ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Infectious diseases · J Antimicrob Chemother · 2026-10-06

In 114 virologically suppressed adults with HIV-1, switching to once-daily doravirine plus raltegravir led to one virological failure by week 48 (1.3%) vs none with continued therapy, and none more through week 96. Three treatment-related adverse events led to stopping.

RCTn = 114
Palich et al. Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL)
Infectious diseases · J Infect Dis · 2026-09-23

Secondary analysis of three phase 3 switch trials (1227 virologically suppressed adults with HIV-1): HIV-1 RNA <50 copies/mL at week 48 on doravirine/islatravir was ≥88% with or without baseline proviral NNRTI RAMs (26.3%) or M184I/V (5.7%).

Secondary analysisn = 1,227
Diamond et al. Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA
Infectious diseases · Clin Infect Dis · 2026-07-23

In 147 people with HIV and obesity on an integrase inhibitor plus TAF/FTC, switching to doravirine with TAF/FTC or TDF/FTC did not produce clinically meaningful differences in weight change at 48 weeks (difference 1.36 and -0.89 percentage points) or metabolic health.

RCTn = 147
Koethe et al. A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391)
Infectious diseases · Lancet HIV · 2026-02-25

Phase 3 non-inferiority RCT in 536 treatment-naive adults with HIV-1: doravirine-islatravir was non-inferior to bictegravir-emtricitabine-tenofovir alafenamide for HIV-1 RNA <50 copies/mL at week 48 (91.8% vs 90.6%); doravirine resistance arose in 2 participants.

RCTn = 536
Rockstroh et al. Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
Infectious diseases · Lancet · 2026-02-07

In 513 virologically suppressed adults with HIV-1, switching to doravirine/islatravir was non-inferior to continuing bictegravir/emtricitabine/tenofovir alafenamide at week 48 (viral load ≥50 copies/mL 1.5% vs 0.6%).

RCTn = 514
Colson et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial
Infectious diseases · Lancet · 2026-02-07

In 551 virologically suppressed adults with HIV-1, switching to doravirine/islatravir was non-inferior to continuing baseline oral ART at week 48 (viral load ≥50 copies/mL 1.4% vs 4.9%); treatment-related adverse events were commoner (12.0% vs 4.9%).

RCTn = 553
Orkin et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.